Research news
- AstraZeneca Fourth quarter and full year results 2011
- 2 February 2012
- AstraZeneca and Karolinska Institutet to create new Translational Sciences Centre
- 2 February 2012
- AstraZeneca and Karolinska Institutet PET Centre Announce Molecular Imaging Research Agreement
- 26 January 2012
- Dr. Briggs Morrison to join AstraZeneca R&D; Dr. Anders Ekblom to lead new Science and Technology function
- 10 January 2012
- Targacept announces decision by AstraZeneca to advance AZD1446 in Alzheimer’s disease
- 5 January 2012
- Dynavax and AstraZeneca agree to conduct toxicology studies for TLR-9 agonist for asthma
- 21 December 2011
- AstraZeneca and Chi-Med enter into global collaboration to co-develop and commercialise novel cancer therapy
- 21 December 2011
- AstraZeneca Enters into Option Agreement to Acquire New Class of Diabetes Assets from Prosidion
- 21 December 2011
- AstraZeneca updates on olaparib and TC-5214 development programmes
- 20 December 2011
- Enlight Biosciences forms new partnerships with AstraZeneca and Novo Nordisk
- 15 December 2011
- AstraZeneca out-licenses imaging agent for amyloid detection to aid diagnosis of Alzheimer’s disease to Neoprobe
- 13 December 2011
- Groundbreaking scientific collaboration gives UK academia access to selected AstraZeneca compounds
- 7 December 2011
AstraZeneca expands postdoc program
We are seeking talented scientists who are interested in pursuing an academic-style Postdoc in a global pharmaceutical setting and contributing to AstraZeneca’s commitment to delivering innovative medicines. This newly expanded internal Postdoctoral research program spans multiple therapeutic areas and a wide range of scientific disciplines.
Discover Partnering with AstraZeneca
AstraZeneca works in partnership with bio companies, academic institutions, governments and not-for-profit organisations, sharing skills, knowledge and resources to achieve a common goal: improved health.